Date Document
20/12/2017 Customer Newsletter - December 2017
15/12/2017 Multi Centre testing commences for AI solution
11/12/2017 Change of Director's Interest Notice
01/12/2017 Appendix 3Y Change of Director's Interest Notice
30/11/2017 Company Secretary Appointment/Resignation
23/11/2017 Results of Meeting
20/11/2017 Change Substantial Shareholder Notification
20/11/2017 Appendix 3Y Change of Director's Interest Notice
31/10/2017 Appendix 4C - quarterly
23/10/2017 Annual Report to shareholders
19/10/2017 Investor Presentation
17/10/2017 Notice of General Meeting/Proxy Form
17/10/2017 Collaborative Partnership to develop new AI Diagnostic tools
17/10/2017 Beta Testing Success for Cloud-Based A.I. Prototype
02/10/2017 Customer Newsletter
28/09/2017 Appendix 4G and Corporate Governance Statement
28/09/2017 Annual Report 2017
30/08/2017 Preliminary Final Report
21/08/2017 Beta Testing Commences for Cloud-Based A.I Prototype
31/07/2017 Appendix 4C - quarterly
17/07/2017 Equity Research Update Report Released
05/07/2017 New Registered Office and Business Address
03/07/2017 Final Director's Interest Notice
30/06/2017 Customer Newsletter - June 2017
29/06/2017 Resignation of Non-Executive Director
22/06/2017 Bone Marrow Iron Assessment Launch
21/06/2017 Leading Patient NGO Endorses FerriScan and AI Technology
14/06/2017 Artificial Intelligence Solution for Emerging Markets
28/04/2017 Quarterly Report
18/04/2017 FerriScan not impacted by Fatty Liver
12/04/2017 Evidence Building for HepaFat-Scan
05/04/2017 Appendix 3Y Panton
30/03/2017 Customer Newsletter - March 2017
23/03/2017 Cancer Survivor Campaign Update
01/03/2017 Updated Securities Trading Policy
28/02/2017 Half year report
09/02/2017 Change in substantial holding
31/01/2017 Appendix 4C - quarterly
12/01/2017 Maylasian NAFLD - Diabetes Study